Biosimilars and interchangeable biologics: strategic elements
1. Introduction to biosimilar and interchangeable products -- 2. Intellectual property issues -- 3. European regulatory guidance -- 4. EMA-approved biosimilars -- 5. The FDA regulatory guidance -- 6. The ROW regulatory guidance -- 7. U.S. commercialization -- 8. Global commercialization -- 9. Quality and lifecycle management.